CONCORDBIO · NSE
Concord Biotech Limited
₹1,494.4
+2.28% (+₹33.3)
Prev. close
₹1,461.1
Volume
1,70,417
Delivery %
34.0%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Concord Biotech Limited
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ankur Vaid
Headquarters
Ahmedabad
Employees
1,624
Website
concordbiotech.comExchange
View on NSE ↗Key stats
Market cap
₹15,633.85 Cr
P/E ratio (TTM)
51.4
Dividend yield
0.52%
EPS (TTM)
₹29.08
Beta (1Y · daily vs NIFTY 50)
0.98
Beta (5Y · monthly vs NIFTY 50)
1.66
Shares float
2.66 Cr
EPS · quarter ended Jun 2026
₹8.46
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹830.63 Cr | ₹1,016.94 Cr | ₹1,200.09 Cr | ₹1,054.89 Cr | |
| EBITDA | — | — | ₹380.56 Cr | ₹465.34 Cr | ₹550.78 Cr | ₹416.48 Cr |
| ₹235.00 Cr | ₹175.00 Cr | ₹240.09 Cr | ₹308.10 Cr | ₹371.64 Cr | ₹260.91 Cr | |
| Diluted EPS | — | — | ₹22.95 | ₹29.45 | ₹35.52 | ₹24.78 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,183.00 Cr | ₹1,313.00 Cr | ₹1,514.00 Cr | ₹1,701.00 Cr | ₹2,034.00 Cr | ₹2,232.00 Cr | |
| — | — | ₹31.55 Cr | ₹9.74 Cr | ₹2.97 Cr | ₹2.32 Cr | |
| Stockholders' equity | ₹1,000.00 Cr | ₹1,104.00 Cr | ₹1,290.00 Cr | ₹1,526.00 Cr | ₹1,812.00 Cr | ₹2,017.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹167.00 Cr | ₹207.00 Cr | ₹246.00 Cr | ₹265.00 Cr | ₹245.00 Cr | ₹267.00 Cr | |
| Investing cash flow | — | — | ₹-157.95 Cr | ₹-154.61 Cr | ₹-159.99 Cr | ₹-142.72 Cr |
| ₹31.00 Cr | ₹-100.00 Cr | ₹-85.00 Cr | ₹-99.00 Cr | ₹-99.00 Cr | ₹-113.00 Cr | |
| Capital expenditure | ₹-204.00 Cr | ₹-156.00 Cr | ₹-145.00 Cr | ₹-86.00 Cr | ₹-111.00 Cr | ₹-95.00 Cr |
| End cash position | — | — | ₹3.50 Cr | ₹15.14 Cr | ₹90.45 L | ₹12.19 Cr |
Investing cash flow, Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 23–Jun 26(12Q) |
|---|---|
| Promoter | 44.08% |
| Public | 55.92% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Concord Biotech Limited | ₹15,285.47 Cr | ₹1,494.4 | 50.2 | 7.58 | 12.9% | 0.00 | -11.3% | -9.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
19 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.